Business
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
Helping clinicians investigate sooner and plan next steps with confidence WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a
About this update from Idexx Laboratories, Inc.
[{"type":"text","content":"\nHelping clinicians investigate sooner and plan next steps with confidence\n\n\n WESTBROOK, Maine--(BUSINESS WIRE)--\nIDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the availability of the IDEXX Cancer Dx™ Panel in the United Kingdom, beginning with early detection of lymphoma in at-risk* dogs. The blood test can be added to panels for sick pets and integrated into regular wellness screenings, with veterinarian pricing starting from £22.50† and results available to UK practices within 3–5 business days.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401831720/en/IDEXX Cancer Dx Panel with lymphoma testing\nCancer remains a leading cause of canine death, with 1 in 4 dogs expected to be diagnosed with cancer in their lifetime.1 Lymphoma, one of the most common cancers, accounts for nearly a quarter of new cancer diagnoses.2 Treatment for canine lymphoma may help extend the lifespan and improve the quality of life for affected dogs, highlighting the critical need for early detection and intervention.\n\n\nResearch indicates that 71% of pet owners in the UK are interested in having a cancer screening test for their pet,3 signalling strong demand for proactive, wellness care.\n\n\nThat momentum is already visible in practice. Since the test launched in North America in 2025, nearly 6,000 veterinary practices across the United States and Canada have integrated the test into diagnostic and wellness workflows.4 The test can detect a lymphoma signal up to eight months before clinical signs appear5– helping clinicians investigate sooner and plan next steps with confidence.\n\n\n“Building on more than 40 years of IDEXX’s leadership in veterinary research and technology development, IDEXX Cancer Dx is an important advancement to deliver unmatched diagnostic insights,” said Jay Mazelsky, President and Chief Executive Officer of IDEXX. “As leaders in key cancer diagnostic categories, like pathology and imaging, we continue to innovate technologies that can redefine how veterinarians approach cancer detection and monitoring in pets. We’re proud to be at the forefront of early cancer detection in dogs and delighted to expand access to reliable cancer testing in the UK.”\n\n\nThe IDEXX Cancer Dx Panel with lymphoma testing...